DUSA's CEO Discusses Q2 2012 Results - Earnings Call Transcript

DUSA Pharmaceuticals Inc. (DUSA)

Q2 2012 Results Earnings Call

August 2, 2012 8:30 AM ET

Executives

Bob Doman – President and CEO

Rich Christopher – Vice President, Finance and CFO

Analysts

Henry Scott – Roth Capital

Nick Halen – Sidoti & Company

Seamus Fernandez – Leerink Swann

Ken Trbovich – C.K. Cooper

Presentation

Operator

Good day, ladies and gentlemen. And welcome to the DUSA Pharmaceuticals Second Quarter 2012 Corporate Highlights and Financial Results Teleconference. At this time, all participants are in a listen-only mode and later, we will conduct a question-and-answer session, and instructions will be given at that time. (Operator Instructions)

As a reminder, this conference is being recorded. I would now like to introduce your host for today’s conference, Bob Doman. Sir, you may begin.

Bob Doman

Good morning, everyone. Thank you for joining us today for our second quarter 2012 corporate highlights and financial results conference call. After some opening comments I’ll turn the call over to Rich Christopher who will cover our financial results.

Please be reminded, while the primary purpose of the call is to review results, be advised that our comments and answers to your questions may contain certain forward-looking statements.

The forward-looking statements are subject to a number of risks and uncertainties associated with the company’s business. Additional information which may affect our business prospects is available in the company’s SEC filings.

We are pleased to report today that DUSA posted a very positive second quarter of the year. Sales results were strong, gross margin dollars were up significantly and we generated $2.3 million in positive cash flow.

If you liked this article you might like

5 Stocks Under $10 Soaring Higher

8 Stocks Under $10 Ripping Higher

DUSA Pharmaceuticals Inc. Stock Upgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Upgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Downgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Downgraded (DUSA)